Partner Therapeutics, Inc. (PTx)
19 Muzzey Street
About Partner Therapeutics, Inc. (PTx)
We're all in for the fight against cancer. Partner Therapeutics (PTx) is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients. We are united in our passion for improving the treatment of cancer and our desire to make a meaningful contribution to outcomes.
The patient is number one. We believe that being a cancer company begins and ends with the patient. We strive to support patient needs throughout their treatment journey to help them make the treatment choices that are right for them and their loved ones.
38 articles with Partner Therapeutics, Inc. (PTx)
Partner Therapeutics, based in Lexington, Mass., has teamed up with the University of Colorado to study mouse models of Down syndrome and compounds that might improve memory with age.
Partner Therapeutics Announces Publication of Results from Pre-Clinical Study Evaluating Recombinant Murine GM-CSF in Mouse Models of Down Syndrome and Normal Aging
Partner Therapeutics, Inc., a commercial biotech company, announces publication of results from investigator-sponsored pre-clinical research evaluating use of recombinant murine GM-CSF to improve cognitive ability and brain pathology in an aged mouse model of Down syndrome and in aged normal mice.
Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure
Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine.
BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients
Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ) to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).
"A Drug Before Its Time?" LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity
Partner Therapeutics, Inc. announced that Frontiers in Immunology published a systematic review of LEUKINE® titled, "Sargramostim as Cancer Therapy and An Immunomodulator.
Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function
Partner Therapeutics, Inc. announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine ) in hospitalized COVID-19 patients.1 This prospective, randomized, controlled, open-label study was conducted at 11 U.S. hospitals.
Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson's Disease
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial ( NCT03790670 ) evaluating the use of Leukine ®
Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)
Focus on non-hospitalized patients based on prior data supporting Leukine's role in improving lung function and enhanced COVID-19 specific immune response
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer's Disease
Patients with mild-to-moderate Alzheimer's disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeutic intervention in AD
Study findings published in Alzheimer's & Dementia: Translational Research and Clinical Interventions suggest Leukine® leads to significant reversal of cognitive impairment and normalizes blood-based biomarkers of dementia in patients with mild-to-moderate Alzheimer’s disease.
Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.
SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function
Treatment with sargramostim was safe, well tolerated and generated T-cells targeted at the SARS-CoV-2 virus, indicating a COVID-19 specific immune response
Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces publication of two pivotal studies that provided the basis for approval of Leukine (sargramostim, yeast-derived rhu GM-CSF) to improve survival in patients expoed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).
9/18/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Experienced industry physician scientist to lead clinical development Co-founder, Dr. Debasish Roychowdhury, to serve as Chief Technology Officer [15-September-2020] LEXINGTON, Mass. , Sept. 15, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock , MD, PhD to serve as the c
9/14/2020It was a busy week for clinical trial updates. Here’s a look.
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the resumption of enrollment in the National Cancer Institute (NCI) sponsored Study EA6141 1 being conducted by ECOG-ACRIN Cancer Research Gro
8/31/2020As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.
Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients
Study builds on extensive research showing that granulocyte-macrophage colony stimulating factor (GM-CSF) is needed for effective immune function in the lungs iLeukPulm Phase 2 Clinical TrIal Supported by $35 Million Contract from U.S. Department of Defense [25-August-2020] LEXINGTON, Mass. , Aug. 25, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a